<DOC>
	<DOCNO>NCT02465944</DOCNO>
	<brief_summary>This study conduct evaluate safety , tolerability efficacy intravenously administer FFP104 placebo 15 day ( 3 total dos ) subject moderate severely active Crohn 's Disease</brief_summary>
	<brief_title>A Pilot Study FFP104 Subjects With Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Inclusion criterion Subjects enter study meet follow criterion : Willing able provide write informed consent . Willing able comply study procedures visit . Male female age 18 75 year , inclusive . Body Mass Index ( BMI ) 1835 kg/m2 . Clinical diagnosis Crohn 's disease involve colon and/or ileum least 3 month Screening confirmed radiological , endoscopic histological evidence . Active Crohn 's disease define Crohn 's Disease Activity Index ( CDAI ) score 220 450 , inclusive , Screening . Active inflammatory disease define Crohn 's Disease Endoscopic Index Severity ( CDEIS ) ≥ 8 ( determined Central Blinded Reader ) Screening . Tumor Necrosis Factor ( TNF ) naïve previously expose single antiTNF agent ( infliximab , adalimumab certolizumab pegol ) treatment discontinue least 8 week prior Screening due inadequate response , loss response intolerance judge Investigator . Must adequate renal hepatic function adjudge Investigator . In good health ( Crohn 's disease ) evidence medical history physical examination . Exclusion criterion Subjects enter study meet none follow criterion : Subjects pregnant , breastfeed , childbearing potential use medically accept form contraception . Presence fistula , ileostomy , colostomy rectal pouch history proctocolectomy total colectomy . Subject ostomy ileoanal pouch ( subject previous ileorectal anastomosis exclude ) . Subject short bowel syndrome determine Investigator . History evidence colonic mucosal dysplasia . Subject currently significant mechanical obstruction ( stenosis ) . Subject current diagnosis ulcerative indeterminate colitis . Immunization live vaccine within 4 week Screening , exception influenza vaccine plan immunization within period study . Active latent tuberculosis ( TB ) tuberculosis infection ; TB assessment prophylaxis perform per local biologicals regulation guideline . Subjects history ongoing chronic recurrent infectious disease within 12 month prior Screening . Positive stool culture Clostridium within last 6 month prior Screening . Use prohibit medications/procedures , include ; Concomitant corticosteroids dos exceed 20 mg/day prednisone ( equivalent ) Concomitant use budesonide Concomitant use antiTNF therapy Subjects receive previous treatment one antiTNF agent Concomitant use cyclosporine , tacrolimus , sirolimus mycophenolate mofetil Prior concomitant use antiα4 integrin nonTNF block biological Use tube enteral feeding , elemental diet , parenteral alimentation start within 2 week prior Screening Leukocytapheresis granulocytapheresis within 2 week prior Screening Use prescription medications/products ( exception prescription medication contraception and/or medication deem acceptable Investigator Sponsor ) . Use counter ( OTC ) , nonprescription preparation ( include vitamin , mineral , phytotherapeutic/herbal/plantderived preparation ) within 7 day prior Checkin visit ( Day 0 ) , unless deem acceptable Investigator Sponsor . Current recent history ( within 6 month screen ) drug substance abuse , include alcohol ≥ 14 unit per week significant history alcoholism drug/chemical abuse within 6 month prior Screening visit ( one unit alcohol equal 0.5 pint [ 285 mL ] beer lager , one glass [ 125 mL ] wine , 1 shot [ 25 mL ] spirit ) . Subjects know clinically significant cardiac disease ( e.g. , myocardial infarction stroke within 6 month prior Screening , unstable angina , claudication , etc . ) , evidence clinically significant electrocardiogram ( ECG ) abnormality Screening . A history significant neurologic , hepatic , renal , endocrine , cardiovascular , gastrointestinal , pulmonary metabolic disease within 30 day Screening visit , judge Investigator . Have family history ( one first degree relative ) multiple thrombotic event personal history venous arterial thrombotic event include deep vein thrombosis , stroke , myocardial infarction , pulmonary embolus , peripheral arterial thromboembolic event . Subject positive hepatitis panel ( include hepatitis B surface antigen [ HBsAg ] , hepatitis B core antibody , hepatitis C virus antibody [ antiHCV ] ) positive HIV antibody screen time Screening . Evidence hepatic dysfunction , viral hepatitis , current chronic history liver disease include nonalcoholic steatohepatitis ( NASH ) abnormal hepatic marker ( AST , ALT , ALP , total bilirubin &gt; 1.5 x upper limit normal ) time Screening visit . Abnormal renal function ( BUN creatinine &gt; 1.25 x upper limit normal ) time Screening visit . White Blood Cells &lt; 4 x 103/mm3 ; platelet &lt; 150 x 103/mm , hemoglobin &lt; 6.2 mmol/L time Screening visit . Subjects evidence serious , significant , acute chronic medical psychiatric illness , judgment Investigator , could compromise subject safety , limit subject 's ability complete study , and/or compromise objective study . History malignancy , exception resect basal cell carcinoma , squamous cell carcinoma skin , resect cervical atypia carcinoma situ . Active acute infection require systemic treatment 2 week . Planned surgery study period undergone major surgery within 3 month prior Screening visit . Subjects received investigational drug within 60 day use experimental antiCD therapy within last 30 day prior Screening visit . Known sensitivity component study drug previous sensitivity reaction clinically significant reaction intravenous medication biologic therapy . Subjects previously receive FFP104 previously enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>inflammation</keyword>
</DOC>